US5169837A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Isolated osteogenic factor
Assignee: Allelix Biopharmaceuticals Inc
•
Filing: 1991-03-28
•
Granted: 1992-12-08
•
Expires: 2011-03-28
Abstract
Abstract Described is a purified osteogenic factor that when delivered to bone in association with a physiologically acceptable delivery vehicle is capable of inducing new bone growth at the bone surface. The osteogenic factor is water soluble, and is characterized physically by a molecular weight of about 2.5 kD when measured by gel filtration under dissociating conditions and an isoelectric point in the pH range from about 4.6 to 7.2. Use of the purified factor in treating bone defects is described. Also described is a method for obtaining the purified factor from mammalian bone.
Inventors
- 👤 Alain E. Lagarde
- 👤 Abdulwahid Abdulwajid
- 👤 Donna Bueschkens
- 👤 Deanna Byrne
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 17:06
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/475; C07K14/51; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/84
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
70 words
An isolated, water-soluble osteogenic factor capable of inducing bone formation in a mammal when delivered to bone in association with a physiologically acceptable delivery vehicle, characterized by a molecular weight of about 2.5 kDa as measured by gel filtration under dissociating conditions, an isoelectric point in the pH range from 4.6 to 7.2, and a specific activity of at least 10 units/mg as determined in the rat bone growth assay.
Claim 2
Dependent Claim
70 words
An isolated, water-soluble osteogenic factor capable of inducing bone formation in a mammal when delivered to bone in association with a physiologically acceptable delivery vehicle, characterized by a molecular weight of about 2.5 kDa as measured by gel filtration under dissociating conditions, an isoelectric point in the pH range from 4.6 to 7.2, and a specific activity of at least 10 units/mg as determined in the rat bone growth assay.
Claim 3
Dependent Claim
26 words
An isolated osteogenic factor according to claim 1, having a specific activity of at least about 600 units/mg as determined in the rat bone growth assay.
Claim 4
Dependent Claim
29 words
An osteogenic factor according to claim 1 in substantially purified form, characterized by migration as an individualized absorbance peak at 214 nm on reversed phase high performance liquid chromatography.
Claim 5
Dependent Claim
10 words
An osteogenic factor according to claim 1, in lyophilized form.
Claim 6
Dependent Claim
10 words
An osteogenic factor according to claim 2, in lyophilized form.
Claim 7
Dependent Claim
10 words
An osteogenic factor according to claim 3, in lyophilized form.
Claim 8
Dependent Claim
34 words
An osteogenic composition which induces bone formation in a mammal when delivered to bone, comprising an effective amount of the isolated, water-soluble osteogenic factor defined in claim 1 and a physiologically acceptable delivery vehicle.
Claim 9
Dependent Claim
18 words
An osteogenic composition according to claim 7, wherein said physiologically acceptable delivery vehicle comprises a bone-compatible matrix material.
Claim 10
Dependent Claim
34 words
An osteogenic composition which induces bone formation in a mammal when delivered to bone, comprising an effective amount of the isolated, water-soluble osteogenic factor defined in claim 2 and, a physiologically acceptable delivery vehicle.
Claim 11
Dependent Claim
18 words
An osteogenic composition according to claim 9, wherein said physiologically acceptable delivery vehicle comprises a bone-compatible matrix material.
Claim 12
Dependent Claim
34 words
An osteogenic composition which induces bone formation in a mammal when delivered to bone, comprising an effective amount of the substantially purified osteogenic factor defined in claim 3 and a physiologically acceptable delivery vehicle.
Claim 13
Dependent Claim
18 words
An osteogenic composition according to claim 11, wherein said physiologically acceptable delivery vehicle comprises a bone-compatible matrix material.
Claim 14
Dependent Claim
13 words
An osteogenic composition according to claim 12, wherein bone-compatible matrix material comprises hydroxyapatite.
Claim 15
Dependent Claim
22 words
An osteogenic composition according to claim 12, wherein said physiologically acceptable vehicle comprises a bone-compatible matrix material and a pharmaceutically acceptable diluent.
Claim 16
Dependent Claim
22 words
An osteogenic composition according to claim 14 wherein said matrix material comprises hydroxyapatite and said diluent is an aqueous buffered saline solution.
Claim 17
Dependent Claim
40 words
A method of inducing bone formation in a mammal in need of treatment to induce bone growth, comprising the step of delivering an osteogenic composition as defined in claim 12 to a bone site at which bone formation is desired.
Claim 18
Dependent Claim
19 words
A method according to claim 16, wherein said osteogenic composition is delivered to bone at a site of fracture.
Claim 19
Dependent Claim
26 words
A method effective to induce bone formation in a mammal according to claim 16, wherein said osteogenic composition is delivered to the bone site by injection.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-12-08 | 1996-06-08 | 1996-12-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-12-08 | 2000-06-08 | 2000-12-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-12-08 | 2004-06-08 | 2004-12-08 | $7700.00 | Window Closed / Lapsed |